Is compulsory licensing the answer to the US’ buying of all Remdesivir?

While Gilead has reserved all of its next 3 months’ production of Remdesivir for the US health department, discussions on compulsory licensing as the appropriate response are now once again relevant in many countries.

But is compulsory licensing realistic at all? Read European Patent Attorney Per Larsen‘s take on the matter.

Is compulsory licensing the answer to the US’ buying of all Remdesivir?